Amgen is planning to build a new state-of-the-art next-generation Biomanufacturing plant at its campus in West Greenwich, Rhode Island. The new plant will be first-of-its-kind in the US.
With the track record of providing a reliable supply of high-standard medicines for patients around the globe, Amgen is now going to build the first-ever commercial Next-Gen Bio Plant in the US.
The Amgen‘s Next Generation Biomanufacturing Plant Unit will be manufacturing products for the US and global market by utilising the best-proven biomanufacturing capabilities.
The plant will be constructed on the 75-acre campus of Amgen at Rhode Island.
The expansion plan is expected to create about 150 highly-skilled manufacturing jobs along with additional 200 construction and validation jobs.
Amgen’s overall investment for Rhode Island site is more than US$1.5 billion till date.
The new plant will comprise multiple innovative technologies into a single facility, which in turn significantly reduce the total operating cost of construction.
All the equipment within the plant will be portable, smaller and disposable, which will provide greater flexibility and speed in manufacturing different medicines simultaneously.
The existing campus of Amgen Rhode Island houses one of the world's largest mammalian protein manufacturing facilities.
Currently, the company’s campus is spread across more than 500,000 square feet consisting of a manufacturing, utility, administrative and laboratory space.
Amgen Foundation is also committed to a future plan of investing more US$4.8 million in Rhode Island.
|California, United States